21-valent pneumococcal conjugate vaccine
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pneumococcal Vaccines
Conditions
Pneumococcal Vaccines, Immunosuppression
Trial Timeline
Jan 1, 2026 → Jun 1, 2027
NCT ID
NCT06271681About 21-valent pneumococcal conjugate vaccine
21-valent pneumococcal conjugate vaccine is a approved stage product being developed by Merck for Pneumococcal Vaccines. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06271681. Target conditions include Pneumococcal Vaccines, Immunosuppression.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06271681 | Approved | Recruiting |
Competing Products
20 competing products in Pneumococcal Vaccines